


Radioprotectin-1

Cat. No.:	HY-114380		
CAS No.:	1622006-09-0		
Molecular Formula:	C ₂₃ H ₁₉ ClN ₂ O ₆ S		
Molecular Weight:	486.92		
Target:	LPL Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (256.72 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.0537 mL	10.2686 mL	20.5373 mL
	5 mM	0.4107 mL	2.0537 mL	4.1075 mL
	10 mM	0.2054 mL	1.0269 mL	2.0537 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype^[1].

IC₅₀ & Target

EC₅₀: 25 nM (murine LPA₂ subtype)^[1]

In Vitro

Radioprotectin-1 is a potent agonist of LPA₂ with an EC₅₀ of 5 pM and functions as a full agonist at the human ortholog of

LPA₂^[1].

Radioprotectin-1 (0-3 μM; 15 minutes) effectively reduces apoptosis induced by γ-irradiation and the radiomimetic drug Adriamycin in cells that expressed LPA₂ either endogenously or after transfection^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MEF cells , IEC-6 cells
Concentration:	0 μM, 0.1 μM, 0.3 μM, 1.0 μM, 3 μM
Incubation Time:	15 minutes
Result:	Protected cells from apoptosis by γ-irradiation- and the radiomimetic chemotherapeutic Adriamycin.

In Vivo

Radioprotectin-1 is a high-potency specific agonist of the murine LPA₂ GPCR ^[1].

Radioprotectin-1 (0.1 mg/kg, 0.3 mg/kg; s.c.; every 12 hours; for 3 days) decreases the mortality of C57BL/6 mice in models of the hematopoietic acute radiation syndromes (HE-ARS) and gastrointestinal acute radiation syndromes (GI-ARS) ^[1].

Radioprotectin-1 exerts its radioprotective and radiomitigative action through specific activation of the upregulated LPA₂ GPCR in Lgr5⁺ stem cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-10 weeks old C57BL/6 female mice bearing total body irradiation (TBI) ^[1]
Dosage:	0.1 mg/kg, 0.3 mg/kg
Administration:	Subcutaneous injection; every 12 hours; for 3 days
Result:	Decreased mortality of C57BL/6 mice in models of the HE-ARS and the GI-ARS.

REFERENCES

[1]. Kuo B, et al. The LPA₂ receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids. Cell Signal. 2018 Nov;51:23-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA